AlphAIAlphAI — Financial news for AI agents
seekingalpha.comNOV 31 min read$CMPS

COMPASS Pathways ADS GAAP EPS of -$0.31 beats by $0.10 (CMPS:NASDAQ)

COMPASS Pathways (CMPS) reported Q3 GAAP EPS of -$0.31, beating estimates by $0.10. The company had $444.0 million in cash as of September 30, 2026, up from $149.6 million at the end of 2025, according to its press release.

Original reporting
seekingalpha.com
Published Nov 3, 2026, 11:38 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$CMPS
Bullish
high confidence
Mentioned
$CMPS
Relevance
7/10
AlphAI data visualization · based on seekingalpha.com
Decision brief

The 30-second read

$CMPSBullishMed
01

Why it matters

The earnings beat and cash buildup could attract short-term buying interest, though the negative EPS still signals ongoing losses.

02

Market read

Earnings surprise provides a short-term catalyst for CMPS, with limited broader market impact.

03

What to watch

Future guidance was not disclosed, and the cash increase may reflect financing rather than operating performance.

Relevance 7/10Novelty 8/10Timing: pre-market today

Background

Compass Pathways plc reported its Q3 2026 earnings, highlighting an EPS beat and a significant rise in cash reserves.

Company-level read

Ticker impact

$CMPSBullishHigh confidence
Context

Q3 GAAP EPS of -$0.31 beat expectations by $0.10 and cash rose to $444M.

Expected impact

likely upward pressure as market prices in the earnings beat

Evidence & confidence

The beat is a fresh primary disclosure with improved cash position, which typically drives short-term buying.

Market effects

Sector

Biotech sector may see modest uplift from a positive earnings surprise.

Regional

Limited to U.S. biotech investors.

Global

Low, as the company is a niche player.

Counterpoint

What could challenge this read

The beat may be modest relative to cash burn; investors could remain cautious.

Key entities

  • company
    Compass Pathways plc

    Biotech firm listed on NASDAQ under CMPS.

Read at source← All news

Related articles

NOV 3
$CMPSMedAI 8/10

Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights

COMPASS Pathways plc (CMPS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Compass Pathways Announces Third Quarter 2026 Financial Results and Business Highlights • Final NDA submission nearing completion and will be filed in the next two weeks • Launch readiness on track for expected launch in H12027, subject to FDA approval • Data from two positive Ph

SEC EDGAR 8-K3 min
NOV 3
$CMPSMedAI 8/10

An extra dose extended a depression treatment’s effect to one year in trial data.

Compass Pathways (CMPS) is nearing completion of its NDA submission for COMP360, a treatment for treatment-resistant depression (TRD), with a filing expected in two weeks. Positive Phase 3 trial data shows durability of effect up to one year. The company aims for a H1 2027 launch, subject to FDA approval. COMP360 is seen as a potential blockbuster with a large market opportunity. Compass also has a late-stage PTSD trial ongoing and a strong cash position into 2028.

stocktitan.net2 min
OCT 26
$CMPSMed

B.Riley reiterates Buy on Compass Pathways stock, $22 target

B.Riley reiterated a Buy rating and $22 target on Compass Pathways (CMPS) after the VA selected sites for psychedelic deployment. CMPS is up 78% over the past year and 62% YTD, trading at $11.15. The company's COMP360 therapy could begin dosing soon, with FDA approval possible within 3-6 months. B.Riley estimates significant revenue potential from VA patients. Analysts highlight positive trial data and strong financial position.

investing.com2 min
OCT 24
$CMPSHighAI 9/10

Tovecimig Plus Paclitaxel Improves ORR vs Paclitaxel Alone in Biliary Tract Cancer

Tovecimig (CTX-009) plus paclitaxel showed improved objective response rates (18.0% vs 5.3%) over paclitaxel alone in advanced biliary tract cancer, meeting the primary endpoint of the phase 2/3 COMPANION-002 trial. Median PFS was 4.7 months vs 2.6 months, but OS was similar (8.9 vs 9.4 months). The trial involved 168 patients and was presented at the 2026 ESMO Congress. According to Compass Therapeutics, the combination represents a promising new strategy for biliary tract cancer.

onclive.com3 min
OCT 16
$CMPSMedAI 8/10

Can Durable Response to Psilocybin Reshape Treatment-Resistant Depression Care?

Compass Pathways presented real-world analyses showing that treatment-resistant depression (TRD) has significant economic burden during treatment-resistant episodes, with costs declining as patients stabilize. Their psilocybin formulation, COMP360, showed sustained clinical benefit in phase 3 trials, with 25% and 39% of participants achieving meaningful symptom reduction in COMP005 and COMP006, respectively, maintained through week 26.

psychiatrictimes.com3 min